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Amyotrophic lateral sclerosis (ALS) is a motoneuron disease characterized by misfolded
proteins aggregation in affected motoneurons. In mutant SOD1 (mutSOD1) ALS models,
aggregation correlates to impaired functions of proteasome and/or autophagy, both
essential for the intracellular chaperone-mediated protein quality control (PQC), and to a
reducedmutSOD1 clearance frommotoneurons. Skeletal muscle cells are also sensitive to
mutSOD1 toxicity, but nomutSOD1 aggregates are formed in these cells, that might better
manage mutSOD1 than motoneurons. Thus, we analyzed in spinal cord and in muscle
of transgenic (tg) G93A-SOD1 mice at presymptomatic (PS, 8 weeks) and symptomatic
(S, 16 weeks) stages, and in age-matched control mice, whether mutSOD1 differentially
modulates relevant PQCplayers, such asHSPB8, BAG3, and BAG1. Possible sex differences
were also considered. No changes of HSPB8, BAG3, and BAG1 at PS stage (8 weeks)
were seen in all tissues examined in tg G93A-SOD1 and control mice. At S stage (16
weeks), HSPB8 dramatically increased in skeletal muscle of tg G93A-SOD1 mice, while a
minor increase occurred in spinal cord of male, but not female tg G93A-SOD1 mice. BAG3
expression increased both in muscle and spinal cord of tg G93A-SOD1 mice at S stage,
BAG1 expression increased only inmuscle of the samemice. Since, HSPB8-BAG3 complex
assists mutSOD1 autophagic removal, we analyzed two well-known autophagic markers,
LC3 and p62. Both LC3 and p62 mRNAs were significantly up-regulated in skeletal muscle
of tg G93A-SOD1 mice at S stage (16 weeks). This suggests that mutSOD1 expression
induces a robust autophagic response specifically in muscle. Together these results
demonstrate that, in muscle mutSOD1-induced autophagic response is much higher than
in spinal cord. In addition, if mutSOD1 exerts toxicity in muscle, this may not be mediated
by misfolded proteins accumulation. It remains unclear whether in muscle mutSOD1
toxicity is related to aberrant autophagy activation.
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INTRODUCTION
Autophagy is a fundamental intracellular degradative path-
way activated to respond to the accumulation of aberrantly
folded (misfolded) proteins (Mizushima and Komatsu, 2011).
Autophagy is required for the cellular protein quality control
(PQC) system, which also includes molecular chaperones and
the ubiquitin-proteasome degradative system (UPS) (Carra et al.,
2012). These systems work together protecting cells particu-
larly sensitive to misfolded protein toxicity, such as motoneurons
(Rusmini et al., 2010; Bendotti et al., 2012; Carra et al., 2013).
Motoneurons are major targets of toxicity in diseases linked to
mutant proteins prone to misfold, such as in amyotrophic lateral
sclerosis (ALS) (Pasinelli and Brown, 2006; Rusmini et al., 2010;
Sau et al., 2011; Strong and Yang, 2011; Carra et al., 2012, 2013;
Robberecht and Philips, 2013). Most ALS cases appear in sporadic
(sALS) forms; only about 10–15% have familial (fALS) history,
and are clinically indistinguishable from sALS. fALSs have been
associated with mutations in different genes, such as the superox-
ide dismutase 1 (SOD1), TARDNA-binding protein 43 (TDP-43),
fused in sarcoma/translocated in liposarcoma protein (FUS/TLS),
optineurin (Robberecht and Philips, 2013), or the C9ORF72 gene
(Dejesus-Hernandez et al., 2011; Renton et al., 2011; Ash et al.,
2013; Lashley et al., 2013; Mori et al., 2013). Notably, also the wild
type (wt) forms of the mutated fALS proteins may show aberrant
behavior in sALS (e.g., oxydized wtSOD1, cleaved C-terminus
of wtTDP-43, etc.) (Neumann et al., 2006; Daoud et al., 2009;
Bosco and Landers, 2010; Bosco et al., 2010), suggesting the exis-
tence of a common pathological mechanism. An explanation for
this is that these proteins (either the modified wt or the mutant
forms) have the propensity to misfold and aggregate forming
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insoluble inclusions that are a key neuropathological hallmark
of ALS. Inclusions may alter several cellular functions, such as
axonal transport, mitochondrial, and/or degradative activities,
thereby leading or contributing to motoneuron death (Pasinelli
and Brown, 2006; Cozzolino et al., 2008; Seetharaman et al.,
2009).
In recent years, emerging evidences support the idea that
also non-neuronal cells (e.g., surrounding astrocytes or Schwann
cells, chemotactically attracted microglial cells, and target muscle
cells) might contribute to disease onset and progression (Boillée
et al., 2006), by making motoneuronal cells more sensitive to
protein toxicity. For example, selective expression of mutant
SOD1 (mutSOD1) in skeletal muscle induced atrophy associ-
ated with the loss of motoneurons in the anterior horn of the
spinal cord (Dobrowolny et al., 2008a; Corti et al., 2009; Wong
and Martin, 2010). However, mutSOD1 largely accumulates in
spinal cord of transgenic mice expressing human G93A-SOD1
(Tg G93A-SOD1) (Cheroni et al., 2005, 2009; Basso et al., 2006,
2009; Bendotti et al., 2012), but not in skeletal muscle of the
same mice at any stage of disease (Galbiati et al., 2012; Wei
et al., 2012); thus, muscle cells better cope with misfolded mut-
SOD1 species than motoneuronal cells. This may be due to an
higher muscular degradative capabilities compared to motoneu-
rons (Onesto et al., 2011). In fact, in both cells, mutSOD1
clearance involves both UPS and autophagy, but both the protea-
some and autophagy activities are higher in muscle cells than in
motoneuronal cells.
The interplay between UPS and autophagy is finely regulated
through a mechanism that involves the co-chaperones BAG1 and
BAG3, which act as a switch between the two pathways (Luders
et al., 2000; Carra et al., 2008a; Gamerdinger et al., 2009; Arndt
et al., 2010; Zhang and Qian, 2011). BAG1 is expressed at rel-
atively higher levels in young tissues, paralleled by higher UPS
activity, while BAG3 is expressed at higher levels in aged tissues,
characterized by higher autophagic activity (Gamerdinger et al.,
2009), and the BAG3:BAG1 ratio determines the fate of client pro-
teins to be degraded through either UPS or autophagy. Indeed,
BAG1 routes substrates to UPS by interacting with a complex
formed by the chaperone HSC70 and the ubiquitinating enzyme
CHIP. UPS overwhelming or impairment, due to misfolded pro-
teins, results in upregulation of BAG3 and its partner, the chap-
erone HSPB8 (a small heat shock protein involved in misfolded
proteins recognition) (Wang et al., 2008; Du et al., 2009; Crippa
et al., 2010b; Gentilella and Khalili, 2011; Carra et al., 2013). The
increased BAG3:BAG1 ratio favors a stoichiometric HSC70/CHIP
complex association to BAG3/HSPB8 complex, allowing the p62-
mediated autophagic removal of CHIP-ubiquitinated substrates
(Crippa et al., 2010b; Gamerdinger et al., 2011; Zhang and Qian,
2011; Carra et al., 2012, 2013). Interestingly, we found that mut-
SOD1 blocks the autophagic flux in motoneurons, but not in
muscle cells (Onesto et al., 2011). This autophagic flux blockage
can be counteracted by HSPB8, which participates together with
BAG3/HSC70/CHIP in the autophagic clearance of several dif-
ferent misfolded proteins (polyQ containing proteins, mutSOD1,
a truncated form of TDP-43) (Carra et al., 2005, 2008a,b, 2013;
Crippa et al., 2010b). In addition, HSPB8 induces translation
attenuation via phosphorylation of eIF2alpha (Carra et al., 2009),
thereby decreasing the amount of aggregation-prone proteins to
levels manageable by PQC.
In this study, we analyzed whether spinal cord, which com-
prises the two main cell targets of SOD1 toxicity, namely
motoneuronal and astroglial cells, and skeletal muscle, differen-
tially activate the HSPB8 mediated PQC system in response to
mutSOD1 in tg G93A-SOD1 mice. The results demonstrate that
the autophagic response of muscle tissue to the mutSOD1 expres-
sion is much higher than that found in the spinal cord of the same
mice, suggesting that if mutSOD1 exerts toxicity in muscle, this
may not be mediated by misfolded protein accumulation.
MATERIALS AND METHODS
ANIMALS
All the procedures involving animals and their care were carried
out following the institutional guidelines and in accordance with
national (D.L. no. 116, G.U. suppl. 40, Feb. 18, 1992), and inter-
national laws and policies (EEC Council Directives 86/609, OJ L
358, 1 DEC.12, 1987), and were approved by the Italian Institute
of Technology Animal Care Committee. All the animals were
kept under controlled temperature and humidity conditions with
standardized dark/light cycles of 12 h each. Food (standard pel-
lets) and water were supplied ad libitum. BL6JL Tg(SOD1)2Gur/J
(Stock number 002297, Charles River, Wilmington, MA, USA)
male mice or BL6JL-Tg(SOD1∗G93A)2Gur/J (Stock number
002726, Charles River) male mice were crossed with wt female
mice purchased (Stock number 100012, Charles River) or
obtained in house by crossing C57Bl/6J female and SJLmale mice.
All the experiments were performed in mice coming from the
F1 generation of the cross described above. Non-transgenic lit-
termates were used as controls (NTg). Mice were genotyped by
PCR on tail DNA as previously described (Gurney et al., 1994),
using REDExtract-N-Amp Tissue PCR kit (Sigma-Aldrich, St.
Louis, MO, USA). To evaluate disease stages, starting from the
8th week of age and twice a week, mice were tested for deficit
by rotarod, and hanging wire by the same operator as previously
described (Palazzolo et al., 2009). Body weight loss was also mon-
itored. Disease onset was set as the time at which the mouse
permanently starts to lose body weight. Four mice per group were
anesthetized with isoflurane and sacrificed at 8 or 16 weeks of
age, corresponding to presymptomatic (PS) or symptomatic (S)
stage of disease. Quadriceps muscles and spinal cord were rapidly
collected after the sacrifice, snap frozen in liquid nitrogen, and
conserved at −80◦C until RNA and protein extraction.
RNA EXTRACTION
Total RNA from frozen spinal cords or muscles was extracted
using the standard TRI Reagent protocol based on the method
developed by Chomczynski and Sacchi (Chomczynski and Sacchi,
1987). RNA was subsequently extracted in accordance to man-
ufacturer’s protocol (Sigma-Aldrich). The precipitated RNA was
dissolved in RNase-free water. Total RNA (1µg) was treated
for 15min at room temperature with 1U of DNaseI (Sigma-
Aldrich). Samples were reverse-transcribed using the High-
Capacity cDNA Reverse Transcription Kit (Life Technologies
Corporation, Carlsbad, CA, USA) according to the manufac-
turer’s instructions, in a 20µL volume. Primers for selected genes
Frontiers in Cellular Neuroscience www.frontiersin.org November 2013 | Volume 7 | Article 234 | 2
Crippa et al. Autophagic power in ALS mice
were designed via the Primer Express software (Life Technologies
Corporation) and purchased from MWG Biotech (Ebersberg,
Germany). Primer sequences were as follows: mouse HSPB8: 5′-
ATA CGT GGA AGT TTC AGG CA -3′ (forward), 5′- TCC TTT
GAC CTA ACG CAA CC -3′ (reverse); mouse BAG3: 5′- ATG
GAC CTG AGC GAT CTC A -3′ (forward), 5′- CAC GGG GAT
GGG GAT GTA -3′ (reverse); mouse BAG1: 5′- GAA ACA CCG
TTG TCA GCA CT -3′ (forward), 5′- GCT CCA CTG TGT CAC
ACT C -3′ (reverse); mouse MAP-LC3b: 5′- CGT CCT GGA CAA
GAC CA -3′ (forward), 5′- CCA TTC ACC AGG AGG AA -
3′ (reverse); mouse p62: 5′- AGG GAA CAC AGC AAG CT -3′
(forward), 5′- GCC AAA GTG TCC ATG TTT CA -3′ (reverse);
mouse GAPDH: 5′-CCA GAA CAT CAT CCC TGC AT-3′ (for-
ward), 5′-CAG TGA GCT TCC CGT TCA-3′ (reverse). The eval-
uated efficiency of each set of primers was close to 100% for both
target and reference gene. Real-time PCR was performed using
the CFX 96 Real Time System (Bio-Rad Laboratories, Hercules,
CA, USA), in a 10µL total volume, using the iTaq SYBR Green
Supermix (BioRad), and with 500 nmol primers. PCR cycling
conditions were as follows: 94◦C for 10min, 40 cycles at 94◦C
for 15 s, and 60◦C for 1min. Melting curve analysis was per-
formed at the end of each PCR assay to control specificity. Data
was expressed as Ct values and used for the relative quantification
of targets with the Ct calculation to give N-fold changes in
gene expression. Values were normalized to those of GAPDH. To
exclude potential bias due to averaging data transformed through
the equation 2−Ct, all statistics were performed with Ct val-
ues. Each experiment was carried out with four independent
samples, and each sample was run in duplicate wells.
The BAG3:BAG1 relative ratio was obtained considering the
group of 8 weeks-old NTg female mice as control for the
basal physiological condition of the PQC system. In partic-
ular, for each sample a single BAG3:BAG1 ratio was deter-
mined [measuring the (BAG3 2−Ct/BAG1 2−Ct)sample] and
the mean BAG3:BAG1 ratio of control was subtracted [(BAG3
2−Ct/BAG1 2−Ct)control]. Finally, the resulting values were
normalized by the mean BAG3:BAG1 ratio of the control 8
weeks-old NTg female mice.
WESTERN BLOTTING AND FILTER RETARDATION ASSAY (WB AND FRA)
Total proteins from frozen spinal cord or muscles were extracted
in 1% SDS using the standard TRI Reagent protocol, in
accordance with the manufacturer’s protocol (Sigma-Aldrich).
Protein concentration was determined with the bicinchoninic
acid method (BCA assay, EuroClone, Pero, Milan, Italy). WB
analysis was performed on 12% sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis loading 15µg of total proteins.
Samples were then electrotransferred to Nitrocellulose membrane
(Bio-Rad) using the Trans-Blot Turbo (Bio-Rad). The mem-
branes were treated with a blocking solution containing 5%
non-fat driedmilk powder (EuroClone) in TBS-T for 1 h and then
incubated with the primary antibodies: (1) home-made rabbit
polyclonal anti-HSPB8 (kindly provided by Dr Jacques Landry,
Quèbec, Canada, dilution 1:1000); (2) rabbit-polyclonal anti-
BAG3 antibody (Abcam, Cambridge, UK; dilution 1:1000); (3)
rabbit-polyclonal anti-BAG1 (Santa Cruz Biotechnology, Dallas,
Texas, USA; dilution 1:1000); (4) rabbit polyclonal anti-LC3
(Sigma; dilution 1:1000); (5) rabbit polyclonal anti-SQSTM1/p62
(Abcam; dilution 1:1000); (6) rabbit-polyclonal anti-GAPDH
(Santa Cruz Biotech; dilution 1:1000); (7) rabbit-polyclonal
anti-SOD1 (SOD-100; StressMarq, Victoria, BC, Canada; dilu-
tion 1:1000). Immunoreactivity was detected using goat anti-
rabbit (sc-2004, Santa Cruz Biotech, dilution 1:5000) secondary
peroxidase-conjugated antibody. Immunoreactivity was then
visualized using the enhanced chemiluminescence detection kit
reagent (ECL prime Western Blotting Substrate, GE Healthcare,
Maidstone, UK). The same membranes were subsequently pro-
cessed with different antibodies to detect the levels of different
proteins in the same samples loaded on the gel, after stripping
for 10min at room temperature (StripABlot, EuroClone). Each
experiment was carried out twice, with four independent samples.
FRA was performed using a slot-blot apparatus (Bio-Rad).
3µg of total proteins were loaded on a 0.2µm cellulose acetate
membrane (Whatman, GE Healthcare), pre-incubated with 20%
methanol, washed with water and then incubated with 1% SDS
solution. After slight vacuumfiltration, slot-blotmembranes were
probed as described for WB.
A ChemiDoc XRS System (Bio-Rad) was used for the image
acquisition of WB and FRA.
STATISTICAL ANALYSIS
Statistical analysis was performed through two-tailed Student
t-test for comparisons between 8 and 16 weeks mice of the same
group (NTg/Tg wtSOD1/Tg G93A-SOD1) and two-way analysis
of variance (ANOVA) for group comparisons, using the PRISM
software (GraphPad, San Diego, CA, USA). Specific group pair(s)
statistical difference was determined by the Bonferroni post-hoc
test. Data were expressed as mean ± SD of four independent
samples.
RESULTS
Our study has been performed on 8 (presymptomatic stage, PS)
and 16 weeks-old (symptomatic stage, S) Tg G93A-SOD1 mice,
compared to age-matched non-transgenic (NTg) and transgenic
human wild-type SOD1 (Tg wtSOD1) mice. In addition, since
gender differences have been reported to affect the age of onset
and disease progression both in ALS patients (Kurtzke, 1982;
Giagheddu et al., 1983; Rudnicki, 1999; Manjaly et al., 2010;
McCombe and Henderson, 2010; Lee et al., 2013a) and rodent
models of ALS (Veldink et al., 2003; Suzuki et al., 2007), withmale
gender being more susceptible, we analyzed males and females
separately. Based on our data on the protective role of HSPB8 in
ALS, which is mediated by autophagy, we analyzed the expression
of this small chaperone in the spinal cord andmuscle of Tg G93A-
SOD1 mice and control mice. We also analyzed the expression
of the two co-chaperones BAG3 and BAG1, which may mediate
the PQC activity by selecting the proper degradative system to be
activated in cells in response to proteotoxicity. Finally, we ana-
lyzed two widely used autophagic markers, LC3 and p62. Using
homogenates of spinal cord and skeletal muscle derived from Tg
G93A-SOD1 mice and age-matched NTg or Tg wtSOD1 mice, we
first compared the levels of wtSOD1 and mutSOD1 in both the
soluble and insoluble fractions in 8 (corresponding to PS stage)
and 16 weeks (corresponding to S stage) male and female mice. As
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shown in Figure 1, soluble monomeric wtSOD1 and mutSOD1
were analyzed by western blot (WB; A: spinal cord; B: muscle).
In the spinal cord of Tg mice the levels of wtSOD1 and mut-
SOD1 proteins were similar, while in skeletal muscle mutSOD1
levels were apparently lower as compared to wtSOD1 and no gen-
der differences were observed. Using motoneuronal and muscle
ALS models as well as tg G93A-SOD1 mice, we recently demon-
strated that mutSOD1 accumulated both in motoneuronal cells
and in spinal cord of tg mice (already at PS, increasing at S stage),
but did not accumulate in ALS muscle cells and ALS muscle tis-
sues at any age tested (Onesto et al., 2011; Galbiati et al., 2012).
These data were recently confirmed and extended byWei and coll.
(Wei et al., 2013) using a different strain of tg G93A-SOD1 mice.
Thus, here we repeated these experiments to provide a general
view of mutSOD1 behavior in our mice. A representative filter
retardation assay (FRA; C: spinal cord;D: muscle) illustrating the
corresponding insoluble fractions of mutSOD1 is reported. The
FRA analysis confirmed the presence of relevant amounts of mut-
SOD1 insoluble species in samples of S stage tg G93A-SOD1mice.
In muscle tissue, no mutSOD1 insoluble species were present,
with the exception of samples obtained from tg G93A-SOD1male
mice at S stage (16 weeks), suggesting that muscle tissue may bet-
ter cope with the misfolded fraction of mutSOD1 as compared to
cells in the spinal cord.
Since we already showed that overexpression of HSPB8 pre-
vents mutSOD1 intracellular accumulation by facilitating its
clearance through autophagy (Crippa et al., 2010a,b), we ana-
lyzed HSPB8 mRNA levels in the spinal cord and skeletal muscle
in response to wt or mutSOD1 expression. In spinal cord, we
observed a significant increase of HSPB8 mRNA transcript lev-
els in response to mutSOD1 expression in S stage (16 weeks)
Tg G93A-SOD1 male mice as compared to age-matched NTg or
Tg wtSOD1mice (Figure 2A) (Crippa et al., 2010b). Interestingly,
Tg G93A-SOD1 female mice did not show any significant increase
of HSPB8 transcript level in response to mutSOD1expression,
suggesting the existence of gender differences in the PQC system
activated by misfolded proteins in spinal cord. In male 16-week-
old NTg mice, the expression level of HSPB8 tended to decrease,
even if it did not become statistically significant. However, we
already shown that HSPB8 expression significantly decreases
when older NTg mice (age-matched with Tg G93A-SOD1 mice
at end stage of disease) were analyzed (Crippa et al., 2010a,b).
In contrast to what we found in spinal cord, in the skeletal mus-
cles of S stage (16 weeks) Tg G93A-SOD1 mice we observed a
dramatic increase of HSPB8 mRNA (up to 8-fold) (Figure 2B).
Importantly, this HSPB8 mRNA upregulation occurred in both
sexes. HSPB8 mRNA levels were unaffected in both sexes in NTg
and Tg wtSOD1 mice at all ages considered.
The robust induction of HSPB8 expression in response to
mutSOD1 in muscle might serve to initiate and/or facilitate the
clearance of aberrant mutSOD1 species. This may avoid the
aggregation of misfolded protein and the accumulation to lev-
els that cannot be managed by the PQC system. Considering that
mutSOD1 species are degraded by the saturable UPS, but it can
be preferentially degraded by the highly efficient autophagic sys-
tem in presence of high levels of HSPB8 (Crippa et al., 2010b)
and that the pro-degradative activity of HSPB8 is mediated by
its partner BAG3, we analyzed the expression levels of BAG3
in both spinal cord and muscle (Carra et al., 2008b; Carra,
2009). We found that in the spinal cord of both male and
female mutSOD1 mice BAG3 expression remains unchanged
at PS stage (8 weeks), but it was significantly increased by
approximately 3-fold compared to NTg or Tg wtSOD1 mice
at S stage (16 weeks, Figure 3A). Furthermore, the mutSOD1-
induced appearance of symptoms correlated with a great response
of the HSPB8-BAG3-mediated PQC system also in muscle
(Figure 3B). Curiously, in female mice, BAG3 expression dif-
fered from that of HSPB8, since it was upregulated by mutSOD1
both in spinal cord and in muscle of tg G93A-SOD1 mice at S
stage.
FIGURE 1 | Biochemical properties of wtSOD1 and mutSOD1 in
spinal cord and muscle of ALS animal models. Western Blot (WB)
analysis and Filter Retardation Assay (FRA) on proteins extracted from
whole spinal cord (A, WB; C, FRA) or quadriceps muscles (B, WB;
D, FRA) of female and male non-transgenic (NTg) mice, of mice
expressing the wild type human SOD1 transgene (wtSOD1), and of
mice expressing the G93A mutant form of human SOD1
(G93A-SOD1), at 8 (corresponding to presymptomatic stage, PS, in Tg
G93A-SOD1 mice) or 16 weeks (corresponding to symptomatic stage,
S, in Tg G93A-SOD1 mice). GAPDH was used to normalize protein
loading. hSOD1, transgenic human SOD1; mSOD1, endogenous
murine SOD1.
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FIGURE 2 | Changes in HSPB8 levels in response to wt or
mutSOD1 expression in spinal cord and muscle of ALS
animal models. RT-qPCRs were performed on total RNA
extracted from whole spinal cord (A) or quadriceps muscles (B)
of female and male non-transgenic (NTg) mice, of mice
expressing the wild type human SOD1 transgene (Tg wtSOD1),
and of mice expressing the G93A mutant form of human SOD1
(Tg G93A-SOD1), at 8 (corresponding to presymptomatic stage,
PS, in Tg G93A-SOD1 mice) or 16 weeks (corresponding to
symptomatic stage, S, in Tg G93A-SOD1 mice). Data have been
normalized to the amount of GAPDH mRNA, expressed relative
to the levels determined in age-matched PS female NTg mice,
taken as internal reference, and expressed as fold changes. Data
are mean ± SD of four independent replicates. (A) ∗∗p < 0.01
vs. age- and sex-matched NTg mice. (B) ∗∗p < 0.01 vs. age- and
sex-matched NTg mice and Tg wt SOD1 mice; ◦◦p < 0.01 vs.
PS (8 weeks) female Tg G93A-SOD1; #p < 0.05 vs. PS
(8 weeks) male Tg G93A-SOD1.
In light of our previous results showing that muscle cells
possess a higher UPS activity with respect to motoneuronal
cells (Onesto et al., 2011), we analyzed the expression of BAG1,
which is involved in the re-routing of the misfolded proteins
to proteasome-mediated substrates degradation. In spinal cord,
BAG1 transcript levels were not affected by mutSOD1 expres-
sion (Figure 3C). On the contrary, BAG1 expression increased
2-folds in the skeletal muscle of S stage Tg G93A-SOD1 mice
compared to all other groups analyzed (Figure 3D). This increase
was similar in both sexes. These data suggest that proteasome-
mediated substrate degradation is highly favored in muscle cells
under proteotoxic conditions (e.g., misfolded mutSOD1 overex-
pression). We also estimated the ratio BAG3:BAG1 in each sample
(Figures 3E,F) and found that this is always more elevated in
muscle tissue, both in control and tg G93A-SOD1 mice, suggest-
ing a predominance of the autophagic pathway, but it reaches
higher levels at S stage of disease in response to mutSOD1. In
the case of spinal cord, the BAG3:BAG1 ratio increases only at S
stage (16 weeks) both in male and female tg G93A-SOD1 mice,
suggesting that misfolded mutSOD1 could be re-routed to the
autophagic system at this stage of disease (possibly not fully
removed because of autophagic flux blockage).
Next, we asked whether the upregulation of the transcript lev-
els of the genes described above results in an increase in protein
expression. As shown in Figure 4, in the spinal cord (A), HSPB8,
BAG1, and BAG3 protein levels correlated with the data of gene
transcription observed in the same mice. In skeletal muscle, we
found that HSPB8, BAG3, and BAG1 were all up-regulated in Tg
G93A-SOD1 mice at the S stage (16 weeks) of disease compared
to Ntg and Tg wtSOD1mice (Figure 4B). In the case of BAG3, the
protein was up-regulated also at the PS stage (8 weeks). Little vari-
ation was observed in Tg G93A-SOD1 mice at S stage, while no
major sex differences were noted. Also these data were perfectly in
line and corroborate the mRNA expression analysis data reported
above.
Since HSPB8 overexpression has beneficial effects in cell mod-
els of fALS, it is upregulated in human tissues from patients,
and its mode of action requires the partner BAG3 and a func-
tional autophagy system, we then analyzed the expression of two
widely used markers of the autophagic flux: LC3 (which is overex-
pressed and associated with the autophagosome when autophagy
is activated) and p62 (which is also upregulated during autophagy
activation and is responsible for the insertion of ubiquitinated
misfolded protein species into the autophagosomes). We found
a moderate increase of LC3 mRNA selectively in the spinal cord
of S stage (16 weeks) Tg G93A-SOD1 female mice (Figure 5A). In
contrast, in skeletal muscle of Tg G93A-SOD1 mice (Figure 5B),
LC3 expression was robustly increased at S stage both in male and
female animals. p62 mRNA levels remained unchanged in spinal
cord (Figure 5C), while they were increased in muscle of S stage
female mice (Figure 5D). Notably, p62 levels increased also in Tg
G93A-SOD1 male mice at S stage, even if this induction was not
statistically significant.
Protein levels of LC3 and p62 as well as the conversion of
free LC3-I to autophagosome-associated lipidated form of LC3-II
were analyzed by WB (Figure 6). In spinal cord samples no
major variations of p62 protein were observed, while the levels
of LC3 protein were higher in Tg G93A-SOD1 mice (Figure 6A).
Surprisingly, no conversion of LC3-I to LC3-II was observed,
suggesting that the autophagic process is not massively activated
in the spinal cord at these stages of disease. In skeletal muscle,
p62 protein levels robustly increased in Tg G93A-SOD1 mice at
both ages and in both sexes (Figure 6B). Moreover, at S stage
(16 weeks), in skeletal muscle samples, the lipidated form of LC3
(LC3-II), which is the only one capable to associate with the newly
formed autophagosomes, was increased in Tg G93A-SOD1 mice.
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FIGURE 3 | BAG3 and BAG1 expression in spinal cord and muscle of
ALS animal models. RT-qPCRs were performed on total RNA extracted
from whole spinal cord (A,C) or quadriceps muscles (B,D) of female
and male non-transgenic (NTg) mice, of mice expressing the wild type
human SOD1 transgene (Tg wtSOD1), and of mice expressing the
G93A mutant form of human SOD1 (Tg G93A-SOD1), at 8
(corresponding to presymptomatic stage, PS, in Tg G93A-SOD1 mice) or
16 weeks (corresponding to symptomatic stage, S, in Tg G93A-SOD1
mice). Data have been normalized to the amount of GAPDH mRNA,
expressed relative to the levels determined in age-matched PS female
NTg mice, taken as internal reference, and expressed as fold changes.
Data are mean ± SD of four independent replicates. (A) RT-qPCR on
BAG3 mRNA expression levels in whole spinal cord. ∗∗p < 0.01 vs. age-
and sex-matched NTg and Tg wtSOD1 mice; ∧p < 0.05 vs. age- and
sex-matched NTg mice; §§p < 0.01 vs. age- and sex-matched Tg wtSOD1
mice. (B) RT-qPCR on BAG3 mRNA expression levels in quadriceps
muscles. ∗∗p < 0.01 vs. age- and sex-matched NTg and Tg wtSOD1
mice; ◦p < 0.05 vs. PS (8 weeks) female Tg G93A-SOD1; ##p < 0.01
vs. PS (8 weeks) male Tg G93A-SOD1. (C) RT-qPCR on BAG1 mRNA
expression levels in whole spinal cord. (D) RT-qPCR on BAG1 mRNA
expression levels in quadriceps muscles. ∗∗p < 0.01 vs. age- and
sex-matched NTg and Tg wtSOD1 mice; ◦p < 0.05 vs. sex-matched PS
(8 weeks) Tg G93A-SOD1. (E) BAG3:BAG1 relative ratio of mRNA
expression levels in whole spinal cord. Data represent variations of the
relative levels of BAG3 and BAG1 normalized over the relative BAG3
and BAG1 levels of age-matched PS (8 weeks) female NTg mice (taken
as internal reference, see Materials and Methods for details). ∗∗p < 0.01
vs. age- and sex-matched NTg and Tg wtSOD1 mice; ##p < 0.01 vs. PS
(8 weeks) male Tg G93A-SOD1. (F) BAG3:BAG1 relative ratio of mRNA
expression levels in quadriceps muscles. Data have been calculated as
in (E). ∗p < 0.05 and ∗∗p < 0.01 vs. age- and sex-matched NTg and Tg
wtSOD1 mice; ◦p < 0.05 vs. PS (8 weeks) male Tg G93A-SOD1.
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FIGURE 4 | HSPB8-BAG1-BAG3 protein levels in spinal cord and
muscle of ALS animal models. Western Blot (WB) analysis on
proteins extracted from whole spinal cord (A) or quadriceps muscles
(B) of female and male non-transgenic (NTg) mice, of mice
expressing the wild type human SOD1 transgene (Tg wtSOD1), and
of mice expressing the G93A mutant form of human SOD1 (Tg
G93A-SOD1), at 8 (corresponding to presymptomatic stage, PS, in
Tg G93A-SOD1 mice) or 16 weeks (corresponding to symptomatic
stage, S, in Tg G93A-SOD1 mice). GAPDH was used to normalize
protein loading.
FIGURE 5 | LC3 and p62 expression in spinal cord and muscle of
ALS animal models. RT-qPCRs were performed on total RNA extracted
from whole spinal cord (A,C) or quadriceps muscles (B,D) of female
and male non-transgenic (NTg) mice, of mice expressing the wild type
human SOD1 transgene (Tg wtSOD1), and of mice expressing the
G93A mutant form of human SOD1 (Tg G93A-SOD1), at 8
(corresponding to presymptomatic stage, PS, in Tg G93A-SOD1 mice) or
16 weeks (corresponding to symptomatic stage, S, in Tg G93A-SOD1
mice). Data have been normalized to the amount of GAPDH mRNA,
expressed relative to the levels determined in age-matched PS female
NTg mice, taken as internal reference, and expressed as fold changes.
Data are mean ± SD of four independent replicates. (A) RT-qPCR on
LC3 mRNA expression levels in whole spinal cord. ∗∗p < 0.01 vs. age-
and sex-matched NTg and Tg wtSOD1 mice. (B) RT-qPCR on LC3
mRNA expression levels in quadriceps muscles. ∧p < 0.05 vs. age- and
sex-matched NTg mice; §§p < 0.01 vs. age- and sex-matched Tg
wtSOD1 mice. (C) RT-qPCR on p62 mRNA expression levels in whole
spinal cord. (D) RT-qPCR on p62 mRNA expression levels in quadriceps
muscles. ∗∗p < 0.01 vs. age- and sex-matched NTg and Tg wtSOD1
mice; ◦◦p < 0.01 vs. PS female (8 weeks) Tg G93A-SOD1.
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FIGURE 6 | Autophagic-markers (p62 and LC-3) protein levels in
spinal cord and muscle of ALS animal models. Western Blot (WB)
analysis on proteins extracted from whole spinal cord (A) or
quadriceps muscles (B) of female and male non-transgenic (NTg)
mice, of mice expressing the wild type human SOD1 transgene (Tg
wtSOD1), and of mice expressing the G93A mutant form of human
SOD1 (Tg G93A-SOD1), at 8 (corresponding to presymptomatic stage,
PS, in Tg G93A-SOD1 mice) or 16 weeks (corresponding to
symptomatic stage, S, in Tg G93A-SOD1 mice). GAPDH was used to
normalize protein loading.
Collectively, these data strongly suggest that muscle, probably
because of higher HSPB8, BAG1, and BAG3 expression, not only
may better cope with misfolded mutant proteins, but also has a
more intense autophagic response power compared to cells in the
spinal cord.
DISCUSSION
In a previous study, we showed that spinal cord and muscle dif-
ferently cope with mutSOD1 (Onesto et al., 2011). In fact, in Tg
G93A-SOD1 mice mutSOD1 tends to accumulate in the spinal
cord, while no accumulation of high molecular weight (HMW)
species was found in muscles (Galbiati et al., 2012). Thus, the spe-
cific ability of spinal cord and skeletal muscle to handle misfolded
protein aggregation and clearance (Cheroni et al., 2005, 2009;
Basso et al., 2006, 2009; Bendotti et al., 2012; Galbiati et al., 2012;
Wei et al., 2012) could be related to differences in their response
to proteotoxicity, mediated by the PQC system. In this study we
further investigated this aspect and found that mutSOD1 poorly
accumulates in skeletal muscle, and only a mild increase of SDS-
insoluble species of mutSOD1 is detectable in this tissue in Tg
G93A-SOD1 male mice at the S stage (16 weeks), but not in
female mice. This suggests that differences in the PQC systemmay
also exist between the two sexes. Consequently, we then evaluated
whether the expression pattern of specific factors of the PQC sys-
tem shows a different expression profile in the spinal cord and
muscle of a tg ALS mice model also considering possible gender
differences.
To this purpose, here, we evaluated whether modifications
occur at the initial stages of the PQC system, by focusing our
attention on the HSPB8-BAG3 mediated pathway, involved in
the autophagic process as well as on BAG1 pathway, involved in
UPS mediated PQC. We then further investigated the autophagic
process, since mutSOD1 induced alterations of UPS have already
been analyzed by several investigators, reviewed in Bendotti et al.
(2012), including us (Onesto et al., 2011). Autophagic response
was analyzed using two well-known autophagic markers: LC3
and p62.
Our data clearly demonstrated that in both spinal cord and
muscle HSPB8, BAG1, and BAG3 expression levels are not
affected at early stage of disease (PS). The HSPB8-mediated PQC
response was induced at the S stage of disease, and this activa-
tion was lower in spinal cord than muscle. Therefore, in spinal
cord, the presence of misfolded mutSOD1 might not be suffi-
cient to induce the activation of the PQC system per se, unless the
disease is in an advanced phase, when motoneurons loss and/or
alterations of muscle structures are present (Crippa et al., 2010b).
Considering BAG3 and BAG1 expression, we found that their
behavior was similar to that observed for HSPB8 at S stage (16
weeks). However, the BAG3 response appeared higher than that
of BAG1, and BAG3 induction was also present in the spinal cord
at S stage. Thus, cells in spinal cord have a lower capability than
muscle cells to activate the HSPB8/BAG3- and BAG1-mediated
PQC responses, and this might explain the larger accumulation
of mutant misfolded proteins in this structure. It is of note that
mutSOD1 expression results in the induction of both HSPB8 and
BAG3 in the same structures, since HSPB8 activity is enhanced
by BAG3 recruitment. Once the HSPB8-BAG3 interaction occurs,
the complex recognizes the misfolded proteins and recruits the
constitutively expressed chaperone HSC70 bound to the CHIP
ubiquitinating enzyme (Arndt et al., 2010), allowing misfolded
proteins removal by autophagy (Carra et al., 2008a,b, 2012, 2013;
Arndt et al., 2010; Crippa et al., 2010b). In fact, CHIP ubiquiti-
nates the target misfolded protein, which is then recognized by
the protein p62 for its delivery to the nascent autophagosome
(Arndt et al., 2010). Thus, HSPB8, BAG3, and the autophagy
pathway may represent key players in the stress response elicited
by mutSOD1 expression. Therefore, changes in their expression
levels may correlate with the efficiency with which spinal cord and
muscle cope with aggregate-prone mutSOD1.
On the other hand, the complex HSC70/CHIP can also asso-
ciate to BAG1 to re-route substrates to UPS. When the protea-
some component of UPS is overwhelmed or impaired by the
misfolded proteins, HSPB8 and BAG3 are both highly induced.
UPS inhibition is indeed a condition which occurs in motoneu-
rons and muscle cells expressing mutSOD1 (Onesto et al., 2011),
and the increase in the BAG3:BAG1 ratio allows BAG3 to
more efficiently direct the HSC70/CHIP–associated substrates to
autophagy for degradation (Zhang and Qian, 2011). Our data
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are in line with this working hypothesis, since in muscle we esti-
mated that the BAG3:BAG1 ratio in tg G93A-SOD1mice at S stage
(16 weeks) is much higher than that observed in control mice.
Conversely, in the spinal cord of tg G93A-SOD1 mice at S stage
the BAG1 response is not detectable.
By following the auophagic response in muscle, our data here
clearly show that at the S stage, muscle cells are still able to
upregulate two essential players of the autophagic process, (a)
p62, which recognizes the CHIP-ubiquitinated misfolded pro-
teins in the HSPB8-BAG3-HSC70-CHIP complex, allowing their
insertion into the autophagosome, and (b) LC3, which, after its
activation to LC3, it is recognized by p62 and assists formation
of autophagosomes. These steps are critical to initiate a correct
autophagic flux required to clear the large excess of misfolded
proteins from the cells during PQC response. This response does
not efficiently take place in the spinal cord, since at S stage (16
weeks), misfolded mutSOD1 does not induce the overexpression
of p62 and LC3, suggesting that the autophagic response in this
structure is not as efficient as it is in muscle. In addition, in spinal
cord very low basal levels of LC3-II form can be detected, suggest-
ing that at these ages very few autophagosomes can be generated
in response to mutSOD1. These data are consistent with previous
reports obtained in the spinal cord of early symptomatic tg G93A-
SOD1 mice, in which the LC3-I to LC3-II conversion, and thus,
autophagy activation, occurs at very low levels, and it efficiently
takes place only after the 17 week of age (Tian et al., 2011; Lee
et al., 2013b). With disease progression, several autophagosomes
appear in spinal cord motoneurons surviving at the end stage
of disease (Li et al., 2008; Crippa et al., 2010b). This autophagic
response can also be selectively activated in different cell types; for
example LC3-I to LC3-II conversion can be visualized in cultured
astrocytes in response to mutSOD1 (Kim et al., 2013).
With regards to the possible gender differences existing in
the pathways here analyzed, we only found that, at S stage in tg
G93A-SOD1 mice, the expression of p62 is significantly induced
in skeletal muscle of female but not in that of male mice. These
observations may help to explain why in skeletal muscle of tg
G93A-SOD1 male mice mutSOD1 tends to accumulate in insol-
uble forms (see above). Interestingly, a mild increase of HSPB8
expression was present in spinal cord at S stage (16 weeks) of
tg G93A-SOD1 male mice, but not in female mice. The molec-
ular mechanism at the basis of this peculiar gender differences
is unknown. Interestingly enough, there is a positive correlation
between mutSOD1 accumulation and HSPB8 expression in the
spinal cord of male tg G93A-SOD1 mice at S stage (16 weeks).
This suggests that HSPB8 gene transcription increases in response
to misfolded species accumulation. These data are in line with
our previous results showing that an UPS impairment (which is
know to result in a further mutSOD1 aggregation), lead to HSPB8
overexpression and stabilization (Crippa et al., 2010a,b; Bendotti
et al., 2012; Carra et al., 2012, 2013). It remains to be determined
why this HSPB8 overproduction fails to clear mutSOD1 insoluble
species via autophagy (Crippa et al., 2010b; Rusmini et al., 2010).
By analysing the molecular and biochemical behavior of mut-
SOD1, we have previously elucidated several potential mecha-
nisms of neurotoxicity associated with accumulation of misfolded
proteins in motoneuronal cells (Sau et al., 2007, 2011; Crippa
et al., 2010a,b; Onesto et al., 2011). For instance, the forma-
tion of HMW mutSOD1 species and aggregation correlated with
an altered intracellular mutSOD1 distribution (Sau et al., 2007;
Crippa et al., 2010b). In these conditions, mutSOD1 nuclear
bioavailability was reduced in motoneuronal, but not in muscle
cells (Sau et al., 2007; Crippa et al., 2010a,b; Onesto et al., 2011),
an aberrant biochemical behavior that may result in a decreased
nuclear protection from free radical species (Sau et al., 2007). In
addition, by evaluating mitochondrial superoxide induced oxida-
tion, using MitoSOX (a mitochondrial specific fluorogenic dye
oxidized by superoxide) in motoneuronal NSC34 cell models
of ALS, we found that mutSOD1 expressing motoneuronal cells
are more sensitive to a superoxide-induced oxidative stress when
compared to wtSOD1 expressing motoneuronal cells (Onesto
et al., 2011). These mitochondrial alterations were not found in
muscle C2C12 cells expressing either wt or mutSOD1 (Onesto
et al., 2011). Therefore, mutSOD1 altered intracellular bioavail-
ability, due to sequestration into aggregates, might result in a less
efficient protection against free radical species damages in dif-
ferent subcellular compartments (Sau et al., 2007; Onesto et al.,
2011).
Our results are in line with a recent report showing that
protein misfolding, mitochondrial dysfunction and muscle loss
are not directly dependent on soluble and aggregated mutSOD1
in skeletal muscle of ALS (Wei et al., 2012). Moreover, soluble
mutSOD1 does not have direct effects on mitochondrial dys-
function as determined by quantifying the release of reactive
oxygen species (ROS) in skeletal muscle mitochondria (Wei et al.,
2012).
Interestingly, dysfunction of skeletal muscle and degeneration
of neuromuscular junctions precede disease onset and motoneu-
rons loss in tg ALS mice (Frey et al., 2000; Fischer et al., 2004).
Notably, while the reduction of mutSOD1 expression in the skele-
tal muscle of tg ALS mice has no effect on disease progression
(Miller et al., 2006), the selective expression of mutSOD1 in skele-
tal muscle induces atrophy and mitochondrial abnormalities in
this tissue (Dobrowolny et al., 2008a; Corti et al., 2009; Wong
andMartin, 2010). Moreover, mutSOD1-induced muscle damage
leads to loss of mutSOD1-negative motoneurons in the anterior
horn of the spinal cord, suggesting that mutSOD1 neurotoxicity
can be exerted at different levels and its restricted expression in
muscle can be sufficient to induce an ALS-like disease in mice
(Dobrowolny et al., 2005, 2008a,b).
The data presented here clarify that mutSOD1 activates dis-
tinct pathogenetic pathways in muscle and motoneuron cells.
In addition, the aggregation-independent mutSOD1 toxicity in
muscle can be monitored at transcriptional levels. In fact, in
our muscle cell models of ALS we observed specific alterations
in the expression of typical genes controlling muscle pathways
activated by nerve injury, or muscular atrophy [e.g., MyoD, myo-
genin (two myogenic regulatory factors), and TGFbeta1, which
are markers for muscle fiber damage or atrophy] (Galbiati et al.,
2012). Thus, muscle cells are able to better manage misfolded
mutSOD1 species, even if misfolding is an intrinsic property
of mutSOD1, and it does not depend on the cell environment
(Dobson, 2003). It remains to be clarified whether the autophagic
activation induced by mutSOD1 in muscle initially protective,
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when excessive, may become one of the toxic events mediating
the deleterious activity associated with thismutant protein (Nassif
and Hetz, 2011; Zhang et al., 2011). This hypothesis has already
been proved in a ALS-related motoneuron disease, the Spinal and
Bulbar Muscular Atrophy (SBMA) linked to an expansion of a
polyQ stretch in the androgen receptor (ARpolyQ) (Poletti, 2004;
Rusmini et al., 2013). Even in this motoneuron disease themutant
ARpolyQ affects both spinal cord and muscle, but it has been
shown that an enhanced autophagy exacerbated skeletal mus-
cle atrophy (Yu et al., 2011). Indeed, the genetic inhibition of
autophagy in muscle, through haploinsufficiency for Beclin-1, a
component of the autophagic initiation complex, mitigates skele-
tal muscle atrophy and prolongs survival of a tg SBMA mouse
model (Yu et al., 2011).
Therefore, the toxicity exerted by mutant misfolded proteins
in muscle cells is probably not related to the classical mecha-
nism of intracellular protein aggregation, but other mechanisms
of toxicity may be involved.
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